ACM
BBNX

Archon Capital Management’s Beta Bionics BBNX Stock Holding History

Archon Capital Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$844K Buy
+53,873
New +$641K 0.34% 40

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Archon Capital Management's BBNX Position: Q2 2026 in Review

Archon Capital Management opened a new position in Beta Bionics (BBNX) in Q2 2026: 53,873 shares worth $844K. The stake represents 0.34% of the portfolio and ranks #40 among its holdings.

134 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Archon Capital Management held 53,873 shares of Beta Bionics worth $844K as of Q2 2026.
  • Beta Bionics was a new Archon Capital Management position in Q2 2026.
  • Beta Bionics made up 0.34% of Archon Capital Management's portfolio in Q2 2026, its #40 holding.
  • 134 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Archon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.